AbCellera Biologics (ABCL) Competitors

CRISPR Therapeutics (NASDAQ:CRSP) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Do insiders & institutionals have more ownership in CRSP or ABCL?

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts recommend CRSP or ABCL?

CRISPR Therapeutics presently has a consensus price target of $71.31, indicating a potential upside of 7.15%. AbCellera Biologics has a consensus price target of $8.75, indicating a potential upside of 71.07%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
AbCellera Biologics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more risk and volatility, CRSP or ABCL?

CRISPR Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.

Which has stronger valuation & earnings, CRSP or ABCL?

AbCellera Biologics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$37.31M	154.05	-$366.25M	-$4.52	-14.72
AbCellera Biologics	$28.83M	52.95	-$162.86M	-$0.56	-9.13

Is CRSP or ABCL more profitable?

AbCellera Biologics has a net margin of -737.56% compared to CRISPR Therapeutics' net margin of -1,023.64%. AbCellera Biologics' return on equity of -15.98% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-1,023.64%	-20.08%	-17.13%
AbCellera Biologics	-737.56%	-15.98%	-12.38%

Does the media prefer CRSP or ABCL?

In the previous week, CRISPR Therapeutics had 21 more articles in the media than AbCellera Biologics. MarketBeat recorded 24 mentions for CRISPR Therapeutics and 3 mentions for AbCellera Biologics. CRISPR Therapeutics' average media sentiment score of 0.46 beat AbCellera Biologics' score of 0.40 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AbCellera Biologics beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.